Page Updated September 28, 2024

Dipesh Uprety, MD

Page Written by

Terri Heimann Oppenheimer

Page Edited by Patient Advocate

Dave Foster

Fact Checked

As a clinician at the Karmanos Cancer Institute in Detroit Michigan, Dr. Dipesh Uprety is actively involved in patient care within the Department of Thoracic Oncology. A specialist in lung cancer, thymoma and thymic carcinomas, and malignant pleural mesothelioma, he is particularly interested in how these challenging forms of cancer respond to treatment, and how they manifest resistance to immunotherapy protocols.[1] 

Education and Career

Dr. Uprety began his medical education in Dharan, Nepal, at the BP Koirala Institute of Health Sciences, where he earned both a Bachelor of Medicine degree and a Bachelor of Surgery degree. Following a move to the United States, he completed a residency in Internal Medicine at Abington-Jefferson Health in Abington, Pennsylvania, and then pursued a fellowship in Hematology and Medical Oncology at Gundersen Health System in La Crosse Wisconsin, where he was named Chief Fellow in his final year. Following his experience in Wisconsin, he completed an advanced fellowship in Thoracic Oncology at the Mayo Clinic in Rochester, Minnesota.

Today, Dr. Uprety is an Assistant Professor in the Department of Medical Oncology at Karmanos Cancer Institute, as well as part of the multidisciplinary team in Thoracic Oncology and the Phase 1 Clinical Trials Program. He is also the Editor in Chief of The Cancer News, a professional publication featuring independent and expert analysis in the field of hematology and oncology.[1]

Professional Memberships

Dr. Uprety is a member of:

• American Society of Clinical Oncology
• American College of Physicians
• International Association for the Study of Lung Cancer

Research

Dr. Diprety is engaged in a significant amount of clinical research, with a special interest in studying mechanisms of resistance to immunotherapy. Active clinical trials that he is currently involved in include:

A Single Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PINNACLE)

• CANCER CATEGORY
  Breast,Gastrointestinal (GI),Gynecologic,Head and Neck,Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors 

• CANCER CATEGORY
  Gastrointestinal (GI),Lung
• AGE GROUP
  Adult
• PHASE
  Phase I

Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor

• CANCER CATEGORY
  Breast,Gastrointestinal (GI),Gynecologic,Head and Neck,Lung,Skin
• AGE GROUP
  Adult
• PHASE
  Phase I

A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Lo

• CANCER CATEGORY
  Breast,Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

• CANCER CATEGORY
  Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung,Skin
• AGE GROUP
  Adult
• PHASE
  Phase II

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase I

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase II

Dr. Uprety has also published more than 100 papers or abstracts including original research, commentaries, editorials, and abstracts in leading journals, and a book chapter. He also presents at national and international conferences.[1]

Terri Heimann Oppenheimer

Writer

Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.

Connect with Terri Heimann Oppenheimer

Dave Foster

Page Editor

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Connect with Dave Foster